
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell Div</journal-id><journal-title>Cell Division</journal-title><issn pub-type="epub">1747-1028</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18764945</article-id><article-id pub-id-type="pmc">2543001</article-id><article-id pub-id-type="publisher-id">1747-1028-3-12</article-id><article-id pub-id-type="doi">10.1186/1747-1028-3-12</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Speeding through cell cycle roadblocks: Nuclear cyclin D1-dependent kinase and neoplastic transformation</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Pontano</surname><given-names>Laura L</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>lpontano@mail.med.upenn.edu</email></contrib><contrib id="A2" corresp="yes" contrib-type="author"><name><surname>Diehl</surname><given-names>J Alan</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>adiehl@mail.med.upenn.edu</email></contrib></contrib-group><aff id="I1"><label>1</label>The Abramson Family Cancer Research Institute, Department of Cancer Biology, University of Pennsylvania, Philadelphia, PA 19104, USA</aff><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>2</day><month>9</month><year>2008</year></pub-date><volume>3</volume><fpage>12</fpage><lpage>12</lpage><ext-link ext-link-type="uri" xlink:href="http://www.celldiv.com/content/3/1/12"/><history><date date-type="received"><day>14</day><month>8</month><year>2008</year></date><date date-type="accepted"><day>2</day><month>9</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Pontano and Diehl; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2008</copyright-year><copyright-holder>Pontano and Diehl; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Pontano
               L
               Laura
               
               lpontano@mail.med.upenn.edu
            </dc:author><dc:title>
            Speeding through cell cycle roadblocks: Nuclear cyclin D1-dependent kinase and neoplastic transformation
         </dc:title><dc:date>2008</dc:date><dcterms:bibliographicCitation>Cell Division 3(1): 12-. (2008)</dcterms:bibliographicCitation><dc:identifier type="sici">1747-1028(2008)3:1&#x0003c;12&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1747-1028</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><p>Mitogenic induction of cyclin D1, the allosteric regulator of CDK4/6, is a key regulatory event contributing to G1 phase progression. Following the G1/S transition, cyclin D1 activation is antagonized by GSK3&#x003b2;-dependent threonine-286 (Thr-286) phosphorylation, triggering nuclear export and subsequent cytoplasmic degradation mediated by the SCF<sup>Fbx4-&#x003b1;Bcrystallin </sup>E3 ubiquitin ligase. Although cyclin D1 overexpression occurs in numerous malignancies, overexpression of cyclin D1 alone is insufficient to drive transformation. In contrast, cyclin D1 mutants refractory to phosphorylation-dependent nuclear export and degradation are acutely transforming. This raises the question of whether overexpression of cyclin D1 is a significant contributor to tumorigenesis or an effect of neoplastic transformation. Significantly, recent work strongly supports a model wherein nuclear accumulation of cyclin D1-dependent kinase during S-phase is a critical event with regard to transformation. The identification of mutations within SCF<sup>Fbx4-&#x003b1;Bcrystallin </sup>ligase in primary tumors provides mechanistic insight into cyclin D1 accumulation in human cancer. Furthermore, analysis of mouse models expressing cyclin D1 mutants refractory to degradation indicate that nuclear cyclin D1/CDK4 kinase triggers DNA re-replication and genomic instability. Collectively, these new findings provide a mechanism whereby aberrations in post-translational regulation of cyclin D1 establish a cellular environment conducive to mutations that favor neoplastic growth.</p></abstract></article-meta></front><body><sec><title>Introduction</title><p>Mitogenic signalling induces transcription and translation of the D-type cyclins, the allosteric regulators of CDK4/6, during G1 phase coupling growth stimuli to cell cycle progression [<xref ref-type="bibr" rid="B1">1</xref>]. Active cyclin D1/CDK4 complexes translocate to the nucleus and phosphorylate the retinoblastoma protein (Rb) and related pocket proteins, thereby triggering E2F-dependent transcription of genes required for S-phase entry [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B6">6</xref>]. The timely expression and accumulation of cyclin D1 is ensured through several mechanisms. Initially, <italic>cyclin D1 </italic>expression requires activation of the Raf-Mek-Erk kinase cascade [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B10">10</xref>]. This increased expression is accompanied by phosphatidylinositol 3-kinase and Akt-dependent increases in cyclin D1 translation and decreased cyclin D1 protein degradation [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B13">13</xref>]. Following the G1/S transition, cyclin D1 is rapidly phosphorylated by GSK3&#x003b2; on Thr-286, triggering CRM1-dependent nuclear export [<xref ref-type="bibr" rid="B13">13</xref>]. Thr-286 phosphorylated cyclin D1 is recognized by Fbx4 and the co-factor &#x003b1;B crystallin and is subsequently poly-ubiquitylated and degraded by the 26S proteasome [<xref ref-type="bibr" rid="B14">14</xref>].</p><p>While cyclin D1 overexpression occurs frequently in human cancer and is considered a causative factor in many tumor types, simple over-expression of wild type cyclin D1 is insufficient to drive neoplastic transformation [<xref ref-type="bibr" rid="B15">15</xref>]. In contrast, cyclin D1 mutants refractory to phosphorylation and subsequent cytoplasmic proteasomal degradation are acutely transforming <italic>in vitro </italic>and <italic>in vivo </italic>[<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>] implying that compartmentalization of cyclin D1 complexes is essential for cell homeostasis. Indeed, mutations that directly impact on cyclin D1 nuclear export and subsequent proteolysis have been identified in human tumors [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>]. However, the occurrence of such mutations is rare compared to the frequency of cyclin D1 overexpression. Implicit to this data, if cyclin D1 is a driver oncogene, its overexpression in many cancers must be secondary to tumor-specific alterations that modify its subcellular location during the cell cycle. Here, we discuss recent work to address these questions.</p><sec><title>Cancer-derived cyclin D1 mutations</title><p>Cyclin D1 overexpression occurs in carcinomas of the breast, esophagus, head and neck, and lung; in a majority of these cases, alterations in gene expression cannot account for its overexpression. Perturbations in cyclin D1 degradation have been suggested as the primary contributor in a large percentage of cases. Indeed mutations that interfere with Thr-286 phosphorylation occur, but are rare. Such mutations have been noted in endometrial and esophageal cancer [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>]. For example, of single-base substitutions in the <italic>CCND1 </italic>gene changing proline-287 (Pro-287) to a serine or threonine residue in endometrioid endometrial carcinoma correlates with overexpression of cyclin D1 in the nucleus of neoplastic cells. Additionally, a 12-base pair in frame deletion corresponding to deletion of amino acids 289&#x02013;292 was reported with overexpression of cyclin D1 [<xref ref-type="bibr" rid="B17">17</xref>]. Significantly, subsequent analyses revealed that disruption of Pro-287 abrogates GSK3&#x003b2;-dependent phosphorylation of Thr-286, resulting in nuclear localization of cyclin D1, and deletion of residues 289&#x02013;292 impairs cyclin D1 binding to CRM1, also resulting in nuclear accumulation [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>].</p><p>In accordance with endometrial cancer studies, recently identified cyclin D1 mutations in esophageal cancer and tumor-derived cell lines also disrupt Thr-286 phosphorylation [<xref ref-type="bibr" rid="B18">18</xref>]. Sequencing of cyclin D1 (<italic>CCND1</italic>) in a panel of 90 patient esophageal carcinomas revealed mutation of Thr-286 to arginine and a deletion of C-terminal residues 266&#x02013;295. Additionally, screening of human tumor-derived esophageal carcinoma cell lines also identified a Pro-287 to alanine mutation in three of these lines [<xref ref-type="bibr" rid="B18">18</xref>].</p><p>Alternative splicing may also contribute to cancer specific accumulation of cyclin D1 proteins that cannot undergo cytoplasmic degradation [<xref ref-type="bibr" rid="B20">20</xref>]. Tumor-specific alternative splicing produces a truncated transcript lacking exon 5, the region encoding the C-terminal Thr-286; this cyclin D1 transcript b (D1b) produces a constitutively nuclear protein refractory to proteasomal degradation [<xref ref-type="bibr" rid="B21">21</xref>]. Current work suggests that D1b may be expressed in up to 40% of primary esophageal carcinomas [<xref ref-type="bibr" rid="B21">21</xref>]. While cyclin D1b stability is only moderately increased relative to wild type protein, it is refractory to nuclear export and therefore exhibits constitutively nuclear localization. As might be anticipated, expression of cyclin D1b promotes neoplastic transformation <italic>in vitro</italic>, much like the phosphorylation-deficient T286A mutant [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B21">21</xref>]. It is currently unclear what determines alterations in cyclin D1 splicing; polymorphisms that occur in the splice-donor site at the exon 4/intron boundary have been implicated. However, cyclin D1b has been detected in cells that do not exhibit polymorphic residues implicating the occurrence of alternative mechanisms [<xref ref-type="bibr" rid="B21">21</xref>].</p></sec><sec><title>Disruption of SCF<sup>Fbx4-&#x003b1;Bcrystallin </sup>function: novel insights into cyclin D1 overexpression</title><p>Cell cycle progression is driven by alternating phases of cyclin expression and destruction. Degradation is coordinated by substrate ubiquitylation and destruction via the 26S proteasome [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>]. Poly-ubiquitylation of substrate proteins is catalyzed by the sequential activity of a ubiquitin activating enzyme (E1), ubiquitin conjugating enzyme (E2), and ubiquitin ligase (E3) [<xref ref-type="bibr" rid="B24">24</xref>]. The Skp1-Cul1-F box (SCF) E3 ubiquitin ligases facilitate polyubiquitylation of phosphorylated substrates; among the substrates are many of the key regulators of G1 progression [<xref ref-type="bibr" rid="B25">25</xref>]. We recently identified the E3 ubiquitin ligase that directs phosphorylation-dependent polyubiquitylation of cyclin D1, SCF<sup>Fbx4-&#x003b1;B crystallin </sup>[<xref ref-type="bibr" rid="B14">14</xref>]. Substrate recognition by this ligase is analogous with Skp2/Cks1 in that it is directed by the F box protein Fbx4 in concert with a cofactor, &#x003b1;B crystallin [<xref ref-type="bibr" rid="B14">14</xref>].</p><p>Given the low frequency of mutations within cyclin D1 that directly impact is turnover, a logical prediction was the occurrence of inactivating mutations in its E3 ligase. The first clue to cyclin D1 ligase involvement came from analysis of several breast cancer cell lines exhibiting increased cyclin D1 half-life without mutations disrupting phosphorylation. These analyses revealed that MCF-7 and MDA-MB-231 cells lack &#x003b1;B crystallin expression as a consequence of chromosome deletions. In addition, tumor microarray analysis of esophageal carcinomas revealed a reduction in both &#x003b1;B crystallin and Fbx4 mRNA levels in tumor tissues [<xref ref-type="bibr" rid="B14">14</xref>]. Collectively, these findings implicated the cyclin D1 ligase as a target in tumorigenesis, with proteins such as &#x003b1;B crystallin or Fbx4 functioning as putative tumor suppressors.</p><p>Significantly, recent assessment of the <italic>Fbx4 </italic>sequence in primary esophageal carcinoma samples identified hemizygous, missense mutations in 14 percent of the tumors; no mutations occurred in &#x003b1;<italic>B crystallin </italic>or <italic>CCND1 </italic>genes in tumors expressing mutated Fbx4. A high percentage of mutations reside within a putative Fbx4 dimerization domain, while others target Ser-12 in the N-terminus. Additionally, one mutation identified within the F box domain results in production of a dominant negative protein incapable of recruiting Skp1 and Cul1[<xref ref-type="bibr" rid="B26">26</xref>]. The residues targeted in cancer suggest a model wherein Fbx4 is phosphorylated on Ser-12 and functions as a dimer. While substrate phosphorylation serves as a critical step in regulating SCF ligase function, several studies indicated that F box proteins such as Fbw7 and &#x003b2;-TrCP can form dimers, potentially regulating ligase activity [<xref ref-type="bibr" rid="B27">27</xref>-<xref ref-type="bibr" rid="B30">30</xref>].</p><p>Further analysis of the cyclin D1 ligase revealed that GSK3&#x003b2;, the kinase responsible for cyclin D1 Thr-286 phosphorylation, also catalyzes phosphorylation of Fbx4 Ser-12. Fbx4 phosphorylation correlates with low cyclin D1 expression during G2/M and early G1, with a marked decrease during cell cycle entry due to growth factor-dependent GSK3&#x003b2; inhibition [<xref ref-type="bibr" rid="B11">11</xref>]. Fbx4 phosphorylation increases again at the G1/S boundary as GSK3&#x003b2; becomes active and temporally controls ligase activation and cyclin D1 phosphorylation. These findings raise the question of how Fbx4 phosphorylation regulates ligase function. Additional work demonstrated that Fbx4 forms homodimers in a phosphorylation- and cell cycle-dependent manner [<xref ref-type="bibr" rid="B26">26</xref>]. Fbx4 homodimerization is dependent on Ser-12 phosphorylation; disruption of this residue impairs the ubiquitylation activity of this ligase [<xref ref-type="bibr" rid="B26">26</xref>].</p><p>The tumorigenic potential of Fbx4 mutations disrupting phosphorylation and dimerization was assessed <italic>in vitro</italic>, revealing that such mutations are indeed transforming [<xref ref-type="bibr" rid="B26">26</xref>]. These findings suggest that mutation of Ser-12 or residues within the Fbx4 dimerization domain impairs ligase function, contributing to cyclin D1 accumulation. Studies over the past several years have identified mutations in both cyclin D1 and its E3 ubiquitin ligase that impair proteasomal degradation and promote nuclear accumulation of cyclin D1/CDK4 complexes (summarized in Table <xref ref-type="table" rid="T1">1</xref>). Therefore, delineating the mechanism underlying nuclear cyclin D1-driven transformation is critical for understanding the role of cyclin D1 in tumorigenesis and development of therapeutic strategies for treatment of cancers overexpressing this protein.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Summary of mutations targeting cyclin D1 phosphorylation or ligase function</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Target</td><td align="left">Mutation</td><td align="left">Consequence</td><td align="left">Tumor Type</td><td align="center">Reference</td></tr></thead><tbody><tr><td align="left">Cyclin D1</td><td align="left">T286R</td><td align="left">Constitutively Nuclear</td><td align="left">Esophageal</td><td align="center">[<xref ref-type="bibr" rid="B18">18</xref>]</td></tr><tr><td align="left">Cyclin D1</td><td align="left">&#x00394;266&#x02013;295</td><td align="left">Constitutively Nuclear</td><td align="left">Esophageal</td><td align="center">[<xref ref-type="bibr" rid="B18">18</xref>]</td></tr><tr><td align="left">Cyclin D1</td><td align="left">P287A</td><td align="left">Constitutively Nuclear</td><td align="left">Tumor-derived esophageal carcinoma cell lines TE3, TE7, and TE12</td><td align="center">[<xref ref-type="bibr" rid="B18">18</xref>]</td></tr><tr><td align="left">Cyclin D1</td><td align="left">P287S/T</td><td align="left">Constitutively Nuclear</td><td align="left">Endometrial</td><td align="center">[<xref ref-type="bibr" rid="B17">17</xref>]</td></tr><tr><td align="left">Cyclin D1</td><td align="left">&#x00394;289&#x02013;292</td><td align="left">Constitutively Nuclear</td><td align="left">Endometrial</td><td align="center">[<xref ref-type="bibr" rid="B17">17</xref>]</td></tr><tr><td align="left">&#x003b1;B crystallin</td><td align="left">Chromosome 11 deletion</td><td align="left">Impaired ligase activity</td><td align="left">Tumor-derived breast cancer cell lines (MCF-7, MDA-MB 231)</td><td align="center">[<xref ref-type="bibr" rid="B14">14</xref>]</td></tr><tr><td align="left">Fbx4</td><td align="left">S8R</td><td align="left">Impaired ligase activity</td><td align="left">Esophageal</td><td align="center">[<xref ref-type="bibr" rid="B26">26</xref>]</td></tr><tr><td align="left">Fbx4</td><td align="left">S12L</td><td align="left">Disrupts phosphorylation</td><td align="left">Esophageal</td><td align="center">[<xref ref-type="bibr" rid="B26">26</xref>]</td></tr><tr><td align="left">Fbx4</td><td align="left">P13S</td><td align="left">Disrupts phosphorylation</td><td align="left">Esophageal</td><td align="center">[<xref ref-type="bibr" rid="B26">26</xref>]</td></tr><tr><td align="left">Fbx4</td><td align="left">L23Q</td><td align="left">Dimerization-deficient</td><td align="left">Esophageal</td><td align="center">[<xref ref-type="bibr" rid="B26">26</xref>]</td></tr><tr><td align="left">Fbx4</td><td align="left">P76T</td><td align="left">Impaired Skp1 binding</td><td align="left">Esophageal</td><td align="center">[<xref ref-type="bibr" rid="B26">26</xref>]</td></tr></tbody></table><table-wrap-foot><p>Mutations disrupting GSK3&#x003b2;-dependent cyclin D1 phosphorylation and nuclear export include mutation of Thr-286, Pro-287, and deletion of residues corresponding to the CRM1 binding site. Mutations targeting the SCF<sup>Fbx4-&#x003b1;B crystallin </sup>E3 ubiquitin ligase result in impaired ligase activity and subsequent cyclin D1/CDK4 accumulation in the nucleus.</p></table-wrap-foot></table-wrap></sec><sec><title>Inhibition of cyclin D1 degradation promotes genomic instability</title><p>Aberrant nuclear accumulation of cyclin D1 during S-phase drives cell transformation <italic>in vitro </italic>and B-cell lymphomagenesis in mice [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>]. Recent evidence links nuclear retention of active cyclin D1/CDK4 complexes with genomic instability, providing a novel mechanism wherein cyclin D1 stabilization initiates tumor formation. Nuclear accumulation of active cyclin D1-dependent kinase was found to interfere with Cdt1 proteolysis [<xref ref-type="bibr" rid="B31">31</xref>]. Cdt1 is a component of the pre-replicative complex that promotes loading of the replicative helicase during late G1 phase [<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B33">33</xref>]. The failure to degrade Cdt1 during S-phase has been shown to contribute to DNA re-replication in several systems [<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B35">35</xref>]. In cells harbouring nuclear cyclin D1, Cdt1 proteolysis was disrupted due to repression of Cul4A and Cul4B expression. Cul4 proteins serve as scaffolds for the E3 ligase that regulates Cdt1 [<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B37">37</xref>]. Ultimately, nuclear cyclin D1/CDK4 complexes facilitate stabilization of Cdt1 during S-phase, with concurrent maintenance of the MCM helicase on chromatin, resulting in DNA re-replication and activation of DNA damage checkpoint signalling [<xref ref-type="bibr" rid="B31">31</xref>].</p><p>Active cyclin D1/CDK4 complexes influence transcriptional regulation of the Cul4 proteins; however, the precise mechanism of regulation remains to be elucidated. Strikingly, impaired cyclin D1 ligase function results in nuclear accumulation of active cyclin D1/CDK4 complexes, accumulation of Cdt1, and triggers cellular transformation analogous to cyclin D1 T286A [<xref ref-type="bibr" rid="B26">26</xref>]. Taken together, data elucidating the role of nuclear cyclin D1 in neoplastic transformation support a model wherein disruption of cyclin D1 phosphorylation or SCF<sup>Fbx4-&#x003b1;Bcrystallin </sup>activation generate genomic instability, ultimately driving tumor formation (Figure <xref ref-type="fig" rid="F1">1</xref>).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Cyclin D1 Regulatory Pathways are Targeted in Human Cancer</bold>. Cyclin D1 protein accumulation is tightly controlled via phosphorylation-dependent proteolysis. Mutations targeting cyclin D1 phosphorylation or degradation contribute to neoplastic transformation. Specific disruption of Thr-286 phosphorylation occurs in endometrial and esophageal carcinoma, while mutations preventing Crm1 binding occur in endometrial cancer. Mutations targeting Fbx4 have been identified in esophageal cancer, and &#x003b1;B crystallin loss occurs in tumor-derived breast carcioma cell lines. Disruption of cyclin D1 proteolysis promotes accumulation of active cyclin D1/CDK4 kinase, triggering DNA re-replication and subsequent genomic instability necessary to drive neoplastic transformation.</p></caption><graphic xlink:href="1747-1028-3-12-1"/></fig><p>Genomic integrity is monitored by cell cycle checkpoints that promote cell cycle arrest or apoptosis upon detection of damaged DNA [<xref ref-type="bibr" rid="B38">38</xref>]. Chronic activation of checkpoints may provide selective pressure for deletion or mutation of critical tumor suppressors such as p53 [<xref ref-type="bibr" rid="B39">39</xref>,<xref ref-type="bibr" rid="B40">40</xref>]. Consistent with this notion, cyclin D1T286A-dependent tumorigenesis is accompanied by activation of the DNA damage checkpoint pathway and loss of p53 [<xref ref-type="bibr" rid="B31">31</xref>]. The deleterious effects of nuclear cyclin D1/CDK4 complexes could then have two different effects on cellular transformation. Chronic checkpoint activation can induce selective pressure for loss of tumor suppressors, thereby providing such cells not only with a growth advantage but also the propensity for additional genomic instability.</p></sec><sec><title>Cyclin D1 protein accumulation in tumors: potential therapeutic strategies</title><p>Provided with this new data suggesting that cyclin D1-dependent kinase contributes to neoplasia at least in part through perturbations in DNA replication and loss of genomic integrity, can we utilize this information for increased therapeutic modalities? One scenario might be to take advantage of the fact that tumors harbouring mutations in cyclin D1 or Fbx4 have a compromised DNA damage checkpoint due to loss of p53. In theory, treatment of normal cells with chemotherapeutic agents that generate DNA crosslinks should trigger an intra S-phase checkpoint, thereby providing an opportunity for repair. Expression of stabilized cyclin D1 should promote maintenance of Cdt1 and MCM complexes and in so doing promote continued origin firing without allowing for repair of damaged DNA, ultimately resulting in mitotic catastrophe. Further work is required to investigate how alterations in cyclin D1 proteolysis might influence cellular responses to DNA damaging therapeutics.</p><p>The alternative is the development of drugs that directly target the kinase subunits that cyclin D1 regulates. If continued activation of CDK4/6 is required for tumor proliferation and survival, such drugs may have significant clinical use. Consistent with this notion of oncogene addiction, treatment of mammary epithelial cells derived from murine tumors harbouring a MMTV-T286A transgene with the CDK4/6 inhibitor PD0332991 [<xref ref-type="bibr" rid="B41">41</xref>] triggered G1 arrest [<xref ref-type="bibr" rid="B42">42</xref>]. Therefore, CDK4/6 activity is a potential target to prevent cyclin D1-driven proliferation.</p></sec><sec><title>Concluding Remarks</title><p>Phosphorylation-dependent nuclear export and subsequent degradation of cyclin D1 is essential to maintain cellular homeostasis. Disruption of this regulatory pathway has been extensively shown to promote neoplastic transformation; however, the precise mechanism of this event has been elusive. Significantly, recent work revealed that nuclear accumulation of active cyclin D1/CDK4 complexes generates genomic instability through a mechanism of Cdt1 stabilization and DNA re-replication. Furthermore, mutations targeting SCF<sup>Fbx4-&#x003b1;B crystallin </sup>in human cancers implicate ligase function in cyclin D1 overexpression and subsequent nuclear accumulation of active cyclin D1/CDK4 complexes. Importantly, GSK3&#x003b2; functions as the master switch, turning on cyclin D1 destruction at the G1/S transition by regulating both ligase activation and cyclin D1 phosphorylation. Given the phenotypic outcome of accumulated nuclear cyclin D1/CDK4 complexes, further mechanistic investigation is required for development of novel therapeutic strategies to promote tumor cell death in cancers overexpressing cyclin D1.</p></sec></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>LLP and JAD contributed to the discussion and preparation of this manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work was supported by CA93237 (NIH); JAD is a Leukemia &#x00026; Lymphoma Society Scholar.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sherr</surname><given-names>CJ</given-names></name></person-group><article-title>Mammalian G1 cyclins</article-title><source>Cell</source><year>1993</year><volume>73</volume><fpage>1059</fpage><lpage>1065</lpage><pub-id pub-id-type="pmid">8513492</pub-id><pub-id pub-id-type="doi">10.1016/0092-8674(93)90636-5</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hatakeyama</surname><given-names>M</given-names></name><name><surname>Brill</surname><given-names>JA</given-names></name><name><surname>Fink</surname><given-names>GR</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>Collaboration of G1 cyclins in the functional inactivation of the retinoblastoma protein</article-title><source>Genes Dev</source><year>1994</year><volume>8</volume><fpage>1759</fpage><lpage>1771</lpage><pub-id pub-id-type="pmid">7958855</pub-id><pub-id pub-id-type="doi">10.1101/gad.8.15.1759</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harbour</surname><given-names>JW</given-names></name><name><surname>Luo</surname><given-names>RX</given-names></name><name><surname>Dei Santi</surname><given-names>A</given-names></name><name><surname>Postigo</surname><given-names>AA</given-names></name><name><surname>Dean</surname><given-names>DC</given-names></name></person-group><article-title>Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1</article-title><source>Cell</source><year>1999</year><volume>98</volume><fpage>859</fpage><lpage>869</lpage><pub-id pub-id-type="pmid">10499802</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81519-6</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calbo</surname><given-names>J</given-names></name><name><surname>Parreno</surname><given-names>M</given-names></name><name><surname>Sotillo</surname><given-names>E</given-names></name><name><surname>Yong</surname><given-names>T</given-names></name><name><surname>Mazo</surname><given-names>A</given-names></name><name><surname>Garriga</surname><given-names>J</given-names></name><name><surname>Grana</surname><given-names>X</given-names></name></person-group><article-title>G1 cyclin/cyclin-dependent kinase-coordinated phosphorylation of endogenous pocket proteins differentially regulates their interactions with E2F4 and E2F1 and gene expression</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>50263</fpage><lpage>50274</lpage><pub-id pub-id-type="pmid">12401786</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M209181200</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leng</surname><given-names>X</given-names></name><name><surname>Noble</surname><given-names>M</given-names></name><name><surname>Adams</surname><given-names>PD</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Harper</surname><given-names>JW</given-names></name></person-group><article-title>Reversal of growth suppression by p107 via direct phosphorylation by cyclin D1/cyclin-dependent kinase 4</article-title><source>Mol Cell Biol</source><year>2002</year><volume>22</volume><fpage>2242</fpage><lpage>2254</lpage><pub-id pub-id-type="pmid">11884610</pub-id><pub-id pub-id-type="doi">10.1128/MCB.22.7.2242-2254.2002</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sherr</surname><given-names>CJ</given-names></name></person-group><article-title>Cancer cell cycles</article-title><source>Science</source><year>1996</year><volume>274</volume><fpage>1672</fpage><lpage>1677</lpage><pub-id pub-id-type="pmid">8939849</pub-id><pub-id pub-id-type="doi">10.1126/science.274.5293.1672</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Albanese</surname><given-names>C</given-names></name><name><surname>Johnson</surname><given-names>J</given-names></name><name><surname>Watanabe</surname><given-names>G</given-names></name><name><surname>Eklund</surname><given-names>N</given-names></name><name><surname>Vu</surname><given-names>D</given-names></name><name><surname>Arnold</surname><given-names>A</given-names></name><name><surname>Pestell</surname><given-names>RG</given-names></name></person-group><article-title>Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions</article-title><source>J Biol Chem</source><year>1995</year><volume>270</volume><fpage>23589</fpage><lpage>23597</lpage><pub-id pub-id-type="pmid">7559524</pub-id><pub-id pub-id-type="doi">10.1074/jbc.270.40.23589</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Winston</surname><given-names>JT</given-names></name><name><surname>Coats</surname><given-names>SR</given-names></name><name><surname>Wang</surname><given-names>YZ</given-names></name><name><surname>Pledger</surname><given-names>WJ</given-names></name></person-group><article-title>Regulation of the cell cycle machinery by oncogenic ras</article-title><source>Oncogene</source><year>1996</year><volume>12</volume><fpage>127</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">8552383</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aktas</surname><given-names>H</given-names></name><name><surname>Cai</surname><given-names>H</given-names></name><name><surname>Cooper</surname><given-names>GM</given-names></name></person-group><article-title>Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1</article-title><source>Mol Cell Biol</source><year>1997</year><volume>17</volume><fpage>3850</fpage><lpage>3857</lpage><pub-id pub-id-type="pmid">9199319</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>M</given-names></name><name><surname>Sexl</surname><given-names>V</given-names></name><name><surname>Sherr</surname><given-names>CJ</given-names></name><name><surname>Roussel</surname><given-names>MF</given-names></name></person-group><article-title>Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1)</article-title><source>Proc Natl Acad Sci U S A</source><year>1998</year><volume>95</volume><fpage>1091</fpage><lpage>1096</lpage><pub-id pub-id-type="pmid">9448290</pub-id><pub-id pub-id-type="doi">10.1073/pnas.95.3.1091</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cross</surname><given-names>DA</given-names></name><name><surname>Alessi</surname><given-names>DR</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name><name><surname>Andjelkovich</surname><given-names>M</given-names></name><name><surname>Hemmings</surname><given-names>BA</given-names></name></person-group><article-title>Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B</article-title><source>Nature</source><year>1995</year><volume>378</volume><fpage>785</fpage><lpage>789</lpage><pub-id pub-id-type="pmid">8524413</pub-id><pub-id pub-id-type="doi">10.1038/378785a0</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vanhaesebroeck</surname><given-names>B</given-names></name><name><surname>Leevers</surname><given-names>SJ</given-names></name><name><surname>Panayotou</surname><given-names>G</given-names></name><name><surname>Waterfield</surname><given-names>MD</given-names></name></person-group><article-title>Phosphoinositide 3-kinases: a conserved family of signal transducers</article-title><source>Trends Biochem Sci</source><year>1997</year><volume>22</volume><fpage>267</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">9255069</pub-id><pub-id pub-id-type="doi">10.1016/S0968-0004(97)01061-X</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diehl</surname><given-names>JA</given-names></name><name><surname>Cheng</surname><given-names>M</given-names></name><name><surname>Roussel</surname><given-names>MF</given-names></name><name><surname>Sherr</surname><given-names>CJ</given-names></name></person-group><article-title>Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization</article-title><source>Genes Dev</source><year>1998</year><volume>12</volume><fpage>3499</fpage><lpage>3511</lpage><pub-id pub-id-type="pmid">9832503</pub-id><pub-id pub-id-type="doi">10.1101/gad.12.22.3499</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>DI</given-names></name><name><surname>Barbash</surname><given-names>O</given-names></name><name><surname>Kumar</surname><given-names>KG</given-names></name><name><surname>Weber</surname><given-names>JD</given-names></name><name><surname>Harper</surname><given-names>JW</given-names></name><name><surname>Klein-Szanto</surname><given-names>AJ</given-names></name><name><surname>Rustgi</surname><given-names>A</given-names></name><name><surname>Fuchs</surname><given-names>SY</given-names></name><name><surname>Diehl</surname><given-names>JA</given-names></name></person-group><article-title>Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex</article-title><source>Mol Cell</source><year>2006</year><volume>24</volume><fpage>355</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">17081987</pub-id><pub-id pub-id-type="doi">10.1016/j.molcel.2006.09.007</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alt</surname><given-names>JR</given-names></name><name><surname>Cleveland</surname><given-names>JL</given-names></name><name><surname>Hannink</surname><given-names>M</given-names></name><name><surname>Diehl</surname><given-names>JA</given-names></name></person-group><article-title>Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation</article-title><source>Genes Dev</source><year>2000</year><volume>14</volume><fpage>3102</fpage><lpage>3114</lpage><pub-id pub-id-type="pmid">11124803</pub-id><pub-id pub-id-type="doi">10.1101/gad.854900</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gladden AB</surname><given-names>WR</given-names><suffix>Aggarwal P, Wasik MA, Diehl JA</suffix></name></person-group><article-title>Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma </article-title><source>Oncogene</source><year>2006</year><volume>25</volume><fpage>998</fpage><lpage>1007</lpage><pub-id pub-id-type="pmid">16247460</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1209147</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moreno-Bueno</surname><given-names>G</given-names></name><name><surname>Rodriguez-Perales</surname><given-names>S</given-names></name><name><surname>Sanchez-Estevez</surname><given-names>C</given-names></name><name><surname>Hardisson</surname><given-names>D</given-names></name><name><surname>Sarrio</surname><given-names>D</given-names></name><name><surname>Prat</surname><given-names>J</given-names></name><name><surname>Cigudosa</surname><given-names>JC</given-names></name><name><surname>Matias-Guiu</surname><given-names>X</given-names></name><name><surname>Palacios</surname><given-names>J</given-names></name></person-group><article-title>Cyclin D1 gene (CCND1) mutations in endometrial cancer</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>6115</fpage><lpage>6118</lpage><pub-id pub-id-type="pmid">12955092</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1206868</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benzeno</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>F</given-names></name><name><surname>Guo</surname><given-names>M</given-names></name><name><surname>Barbash</surname><given-names>O</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Herman</surname><given-names>JG</given-names></name><name><surname>Klein</surname><given-names>PS</given-names></name><name><surname>Rustgi</surname><given-names>A</given-names></name><name><surname>Diehl</surname><given-names>JA</given-names></name></person-group><article-title>Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1</article-title><source>Oncogene</source><year>2006</year><volume>25</volume><fpage>6291</fpage><lpage>6303</lpage><pub-id pub-id-type="pmid">16732330</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1209644</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benzeno</surname><given-names>S</given-names></name><name><surname>Diehl</surname><given-names>JA</given-names></name></person-group><article-title>C-terminal sequences direct cyclin D1-CRM1 binding</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>56061</fpage><lpage>56066</lpage><pub-id pub-id-type="pmid">15513923</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M411910200</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Betticher</surname><given-names>DC</given-names></name><name><surname>Thatcher</surname><given-names>N</given-names></name><name><surname>Altermatt</surname><given-names>HJ</given-names></name><name><surname>Hoban</surname><given-names>P</given-names></name><name><surname>Ryder</surname><given-names>WD</given-names></name><name><surname>Heighway</surname><given-names>J</given-names></name></person-group><article-title>Alternate splicing produces a novel cyclin D1 transcript</article-title><source>Oncogene</source><year>1995</year><volume>11</volume><fpage>1005</fpage><lpage>1011</lpage><pub-id pub-id-type="pmid">7675441</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>F</given-names></name><name><surname>Gladden</surname><given-names>AB</given-names></name><name><surname>Diehl</surname><given-names>JA</given-names></name></person-group><article-title>An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>7056</fpage><lpage>7061</lpage><pub-id pub-id-type="pmid">14612495</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>T</given-names></name><name><surname>Rosenthal</surname><given-names>ET</given-names></name><name><surname>Youngblom</surname><given-names>J</given-names></name><name><surname>Distel</surname><given-names>D</given-names></name><name><surname>Hunt</surname><given-names>T</given-names></name></person-group><article-title>Cyclin: a protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division</article-title><source>Cell</source><year>1983</year><volume>33</volume><fpage>389</fpage><lpage>396</lpage><pub-id pub-id-type="pmid">6134587</pub-id><pub-id pub-id-type="doi">10.1016/0092-8674(83)90420-8</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glotzer</surname><given-names>M</given-names></name><name><surname>Murray</surname><given-names>AW</given-names></name><name><surname>Kirschner</surname><given-names>MW</given-names></name></person-group><article-title>Cyclin is degraded by the ubiquitin pathway</article-title><source>Nature</source><year>1991</year><volume>349</volume><fpage>132</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">1846030</pub-id><pub-id pub-id-type="doi">10.1038/349132a0</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ciechanover</surname><given-names>A</given-names></name></person-group><article-title>The ubiquitin-proteasome proteolytic pathway</article-title><source>Cell</source><year>1994</year><volume>79</volume><fpage>13</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">7923371</pub-id><pub-id pub-id-type="doi">10.1016/0092-8674(94)90396-4</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Skowyra</surname><given-names>D</given-names></name><name><surname>Craig</surname><given-names>KL</given-names></name><name><surname>Tyers</surname><given-names>M</given-names></name><name><surname>Elledge</surname><given-names>SJ</given-names></name><name><surname>Harper</surname><given-names>JW</given-names></name></person-group><article-title>F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex</article-title><source>Cell</source><year>1997</year><volume>91</volume><fpage>209</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">9346238</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80403-1</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barbash</surname><given-names>O</given-names></name><name><surname>Zamfirova</surname><given-names>P</given-names></name><name><surname>Lin</surname><given-names>DI</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Nakagawa</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>F</given-names></name><name><surname>Rustgi</surname><given-names>AK</given-names></name><name><surname>Diehl</surname><given-names>JA</given-names></name></person-group><article-title>Mutations in Fbx4 Inhibit Dimerization of the SCF(Fbx4) Ligase and Contribute to Cyclin D1 Overexpression in Human Cancer</article-title><source>Cancer Cell</source><year>2008</year><volume>14</volume><fpage>68</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">18598945</pub-id><pub-id pub-id-type="doi">10.1016/j.ccr.2008.05.017</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Orlicky</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Willems</surname><given-names>A</given-names></name><name><surname>Neculai</surname><given-names>D</given-names></name><name><surname>Ceccarelli</surname><given-names>D</given-names></name><name><surname>Mercurio</surname><given-names>F</given-names></name><name><surname>Shilton</surname><given-names>BH</given-names></name><name><surname>Sicheri</surname><given-names>F</given-names></name><name><surname>Tyers</surname><given-names>M</given-names></name></person-group><article-title>Suprafacial orientation of the SCFCdc4 dimer accommodates multiple geometries for substrate ubiquitination</article-title><source>Cell</source><year>2007</year><volume>129</volume><fpage>1165</fpage><lpage>1176</lpage><pub-id pub-id-type="pmid">17574027</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2007.04.042</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Welcker</surname><given-names>M</given-names></name><name><surname>Clurman</surname><given-names>BE</given-names></name></person-group><article-title>Fbw7/hCDC4 dimerization regulates its substrate interactions</article-title><source>Cell Div</source><year>2007</year><volume>2</volume><fpage>7</fpage><pub-id pub-id-type="pmid">17298674</pub-id><pub-id pub-id-type="doi">10.1186/1747-1028-2-7</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Koepp</surname><given-names>DM</given-names></name></person-group><article-title>Fbw7 isoform interaction contributes to cyclin E proteolysis</article-title><source>Mol Cancer Res</source><year>2006</year><volume>4</volume><fpage>935</fpage><lpage>943</lpage><pub-id pub-id-type="pmid">17189384</pub-id><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-06-0253</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Chiba</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Fujita</surname><given-names>T</given-names></name><name><surname>Ikenoue</surname><given-names>T</given-names></name><name><surname>Omata</surname><given-names>M</given-names></name><name><surname>Furuichi</surname><given-names>K</given-names></name><name><surname>Shikama</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name></person-group><article-title>Homodimer of two F-box proteins betaTrCP1 or betaTrCP2 binds to IkappaBalpha for signal-dependent ubiquitination</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>2877</fpage><lpage>2884</lpage><pub-id pub-id-type="pmid">10644755</pub-id><pub-id pub-id-type="doi">10.1074/jbc.275.4.2877</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>P</given-names></name><name><surname>Lessie</surname><given-names>MD</given-names></name><name><surname>Lin</surname><given-names>DI</given-names></name><name><surname>Pontano</surname><given-names>L</given-names></name><name><surname>Gladden</surname><given-names>AB</given-names></name><name><surname>Nuskey</surname><given-names>B</given-names></name><name><surname>Goradia</surname><given-names>A</given-names></name><name><surname>Wasik</surname><given-names>MA</given-names></name><name><surname>Klein-Szanto</surname><given-names>AJ</given-names></name><name><surname>Rustgi</surname><given-names>AK</given-names></name><name><surname>Bassing</surname><given-names>CH</given-names></name><name><surname>Diehl</surname><given-names>JA</given-names></name></person-group><article-title>Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication</article-title><source>Genes Dev</source><year>2007</year><volume>21</volume><fpage>2908</fpage><lpage>2922</lpage><pub-id pub-id-type="pmid">18006686</pub-id><pub-id pub-id-type="doi">10.1101/gad.1586007</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maiorano</surname><given-names>D</given-names></name><name><surname>Moreau</surname><given-names>J</given-names></name><name><surname>Mechali</surname><given-names>M</given-names></name></person-group><article-title>XCDT1 is required for the assembly of pre-replicative complexes in Xenopus laevis</article-title><source>Nature</source><year>2000</year><volume>404</volume><fpage>622</fpage><lpage>625</lpage><pub-id pub-id-type="pmid">10766247</pub-id><pub-id pub-id-type="doi">10.1038/35007104</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nishitani</surname><given-names>H</given-names></name><name><surname>Lygerou</surname><given-names>Z</given-names></name><name><surname>Nishimoto</surname><given-names>T</given-names></name><name><surname>Nurse</surname><given-names>P</given-names></name></person-group><article-title>The Cdt1 protein is required to license DNA for replication in fission yeast</article-title><source>Nature</source><year>2000</year><volume>404</volume><fpage>625</fpage><lpage>628</lpage><pub-id pub-id-type="pmid">10766248</pub-id><pub-id pub-id-type="doi">10.1038/35007110</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Blow</surname><given-names>JJ</given-names></name></person-group><article-title>Cdt1 downregulation by proteolysis and geminin inhibition prevents DNA re-replication in Xenopus</article-title><source>Embo J</source><year>2005</year><volume>24</volume><fpage>395</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">15616577</pub-id><pub-id pub-id-type="doi">10.1038/sj.emboj.7600520</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vaziri</surname><given-names>C</given-names></name><name><surname>Saxena</surname><given-names>S</given-names></name><name><surname>Jeon</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Murata</surname><given-names>K</given-names></name><name><surname>Machida</surname><given-names>Y</given-names></name><name><surname>Wagle</surname><given-names>N</given-names></name><name><surname>Hwang</surname><given-names>DS</given-names></name><name><surname>Dutta</surname><given-names>A</given-names></name></person-group><article-title>A p53-dependent checkpoint pathway prevents rereplication</article-title><source>Mol Cell</source><year>2003</year><volume>11</volume><fpage>997</fpage><lpage>1008</lpage><pub-id pub-id-type="pmid">12718885</pub-id><pub-id pub-id-type="doi">10.1016/S1097-2765(03)00099-6</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nishitani</surname><given-names>H</given-names></name><name><surname>Sugimoto</surname><given-names>N</given-names></name><name><surname>Roukos</surname><given-names>V</given-names></name><name><surname>Nakanishi</surname><given-names>Y</given-names></name><name><surname>Saijo</surname><given-names>M</given-names></name><name><surname>Obuse</surname><given-names>C</given-names></name><name><surname>Tsurimoto</surname><given-names>T</given-names></name><name><surname>Nakayama</surname><given-names>KI</given-names></name><name><surname>Nakayama</surname><given-names>K</given-names></name><name><surname>Fujita</surname><given-names>M</given-names></name><name><surname>Lygerou</surname><given-names>Z</given-names></name><name><surname>Nishimoto</surname><given-names>T</given-names></name></person-group><article-title>Two E3 ubiquitin ligases, SCF-Skp2 and DDB1-Cul4, target human Cdt1 for proteolysis</article-title><source>Embo J</source><year>2006</year><volume>25</volume><fpage>1126</fpage><lpage>1136</lpage><pub-id pub-id-type="pmid">16482215</pub-id><pub-id pub-id-type="doi">10.1038/sj.emboj.7601002</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>W</given-names></name><name><surname>Feng</surname><given-names>H</given-names></name><name><surname>Santiago</surname><given-names>FE</given-names></name><name><surname>Kipreos</surname><given-names>ET</given-names></name></person-group><article-title>CUL-4 ubiquitin ligase maintains genome stability by restraining DNA-replication licensing</article-title><source>Nature</source><year>2003</year><volume>423</volume><fpage>885</fpage><lpage>889</lpage><pub-id pub-id-type="pmid">12815436</pub-id><pub-id pub-id-type="doi">10.1038/nature01747</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kastan</surname><given-names>MB</given-names></name><name><surname>Bartek</surname><given-names>J</given-names></name></person-group><article-title>Cell-cycle checkpoints and cancer</article-title><source>Nature</source><year>2004</year><volume>432</volume><fpage>316</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">15549093</pub-id><pub-id pub-id-type="doi">10.1038/nature03097</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bartkova </surname><given-names>J</given-names><suffix>Horejs&#x000ed; Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J, Bartek J</suffix></name></person-group><article-title>DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis </article-title><source>Nature</source><year>2005</year><volume>434</volume><fpage>864</fpage><lpage>870</lpage><pub-id pub-id-type="pmid">15829956</pub-id><pub-id pub-id-type="doi">10.1038/nature03482</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gorgoulis </surname><given-names>VG</given-names><suffix>Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA Jr, Kastrinakas NG, Levy B, Kletsas D, Yoneta A, Herlyn M, Kittas C, Halazonetis TD</suffix></name></person-group><article-title>Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions </article-title><source>Nature</source><year>2005</year><volume>434</volume><fpage>907</fpage><lpage>913</lpage><pub-id pub-id-type="pmid">15829965</pub-id><pub-id pub-id-type="doi">10.1038/nature03485</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fry</surname><given-names>DW</given-names></name><name><surname>Harvey</surname><given-names>PJ</given-names></name><name><surname>Keller</surname><given-names>PR</given-names></name><name><surname>Elliott</surname><given-names>WL</given-names></name><name><surname>Meade</surname><given-names>M</given-names></name><name><surname>Trachet</surname><given-names>E</given-names></name><name><surname>Albassam</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Leopold</surname><given-names>WR</given-names></name><name><surname>Pryer</surname><given-names>NK</given-names></name><name><surname>Toogood</surname><given-names>PL</given-names></name></person-group><article-title>Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts</article-title><source>Mol Cancer Ther</source><year>2004</year><volume>3</volume><fpage>1427</fpage><lpage>1438</lpage><pub-id pub-id-type="pmid">15542782</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>DI</given-names></name><name><surname>Lessie</surname><given-names>MD</given-names></name><name><surname>Gladden</surname><given-names>AB</given-names></name><name><surname>Bassing</surname><given-names>CH</given-names></name><name><surname>Wagner</surname><given-names>KU</given-names></name><name><surname>Diehl</surname><given-names>JA</given-names></name></person-group><article-title>Disruption of cyclin D1 nuclear export and proteolysis accelerates mammary carcinogenesis</article-title><source>Oncogene</source><year>2007</year><volume>27</volume><fpage>1231</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">17724472</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1210738</pub-id></citation></ref></ref-list></back></article>


